XML 60 R49.htm IDEA: XBRL DOCUMENT
v3.21.1

Revenue (Details) $ in Millions | 3 Months Ended |
--- | --- | ---
Mar. 31, 2021 USD ($) units | Mar. 31, 2020 USD ($) | Dec. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items] |  |  |
Emerging Markets total countries | units | 20 |  |
Net sales | $ 2,752 | $ 2,543 |
Contract with Customer, Liability [Abstract] |  |  |
Contract with Customer, Liability | 403 |  | $ 395
Change in Contract with Customer, Liability [Abstract] |  |  |
Contract with Customer, Liability, Revenue Recognized | 36 |  |
United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,586 | 1,489 |
International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,166 | 1,054 |
Emerging Markets [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 317 | 273 |
Global Endoscopy (Endo) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 499 | 442 |
Global Endoscopy (Endo) Reporting Unit [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 280 | 256 |
Global Endoscopy (Endo) Reporting Unit [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 219 | 186 |
Global Urology (Uro) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 361 | 332 |
Global Urology (Uro) Reporting Unit [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 257 | 237 |
Global Urology (Uro) Reporting Unit [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 104 | 95 |
Global CRM Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 469 | 437 |
Global CRM Reporting Unit [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 276 | 255 |
Global CRM Reporting Unit [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 193 | 182 |
Global Electrophysiology (EP) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 83 | 74 |
Global Electrophysiology (EP) Reporting Unit [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 30 | 32 |
Global Electrophysiology (EP) Reporting Unit [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 53 | 43 |
Global Neuromodulation (NM) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 198 | 191 |
Global Neuromodulation (NM) Reporting Unit [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 151 | 151 |
Global Neuromodulation (NM) Reporting Unit [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 46 | 40 |
Global Interventional Cardiology (IC) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 696 | 633 |
Global Interventional Cardiology (IC) Reporting Unit [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 343 | 297 |
Global Interventional Cardiology (IC) Reporting Unit [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 352 | 336 |
Global Peripheral Interventions (PI) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 433 | 392 |
Global Peripheral Interventions (PI) Reporting Unit [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 238 | 224 |
Global Peripheral Interventions (PI) Reporting Unit [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 195 | 168 |
Specialty Pharmaceuticals [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 13 | 41 |
Specialty Pharmaceuticals [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 10 | 37 |
Specialty Pharmaceuticals [Member] | International [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 4 | 4 |
BSX Reportable Segments [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,739 | 2,502 |
BSX Reportable Segments [Member] | United States |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,577 | 1,452 |
BSX Reportable Segments [Member] | EMEA [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 604 | 552 |
BSX Reportable Segments [Member] | APAC [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 473 | 409 |
BSX Reportable Segments [Member] | Latin America and Canada [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | $ 85 | $ 89 |

X
- Definition Emerging Markets total number of countries + References No definition available. + Details
Name: | bsx_EmergingMarketstotalnumberofcountries
Namespace Prefix: | bsx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ChangeInContractWithCustomerLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ContractWithCustomerLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_EmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalCrmReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalElectrophysiologyEpReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalInterventionalCardiologyIcReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_SpecialtyPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_BSXReportableSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_EMEAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaPacificMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_LatinAmericaandCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |